{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:10:57Z","timestamp":1788189057888,"version":"build-2803163510"},"reference-count":41,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Skin Research and Technology"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitiligo is a chronic autoimmune disorder marked by the loss of melanocytes, causing depigmented patches across the skin. Affecting up to 2% of the global population, vitiligo presents significant psychological impacts, particularly in those with darker skin types. Current hypotheses attribute its etiology to autoimmune destruction, genetic predisposition, and environmental triggers like trauma and stress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A comprehensive review of recent studies was conducted using PubMed and Google Scholar, focusing on systemic treatments for vitiligo, particularly JAK inhibitors (ruxolitinib, upadacitinib, tofacitinib, ritlecitinib, and baricitinib). Eligible studies included trials and case reports on adults with vitiligo evaluating treatment efficacy, safety, and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Topical ruxolitinib has achieved the highest efficacy in repigmenting facial and sun\u2010exposed areas, particularly when combined with phototherapy. Emerging evidence supports oral Janus kinase (JAK) inhibitors, especially upadacitinib and tofacitinib, for their repigmenting effects in refractory cases, though side effects like acne and neutropenia warrant monitoring. Limited evidence supports methotrexate and minocycline as adjunct therapies, with minor repigmentation observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Advances in systemic and topical JAK inhibitors have shown promising repigmentation effects in vitiligo, particularly for localized facial lesions. Ruxolitinib cream, the first FDA\u2010approved therapy, and other JAK inhibitors highlight a growing therapeutic approach, with ongoing trials needed to optimize efficacy and evaluate long\u2010term safety. Combination therapy with phototherapy shows enhanced repigmentation outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/srt.70276","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:43:23Z","timestamp":1761061403000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vitiligo: Ruxolitinib and Other Oral Treatment Options Beyond Ruxolitinib"],"prefix":"10.1111","volume":"31","author":[{"given":"Hira","family":"Ghani","sequence":"first","affiliation":[{"name":"Department of Dermatology The Warren Alpert Medical School of Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5756-6609","authenticated-orcid":false,"given":"Isabella J.","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology Robert Wood Johnson Medical School\u2013Rutgers University  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Ghofrani","sequence":"additional","affiliation":[{"name":"Philadelphia College of Osteopathic Medicine  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7544-0418","authenticated-orcid":false,"given":"Madeline","family":"Tchack","sequence":"additional","affiliation":[{"name":"Department of Dermatology Robert Wood Johnson Medical School\u2013Rutgers University  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Dermatology Robert Wood Johnson Medical School\u2013Rutgers University  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100749.2006.00355.x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20104632.2011.05377.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(14)60763\u20107"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2005.10.001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010017\u20108622\u20107"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.152"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2272"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.2012.11197.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00290"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.048"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14356"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/der2.142"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010022\u201000752\u20106"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19162"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221143748"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1016"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20109"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102655"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200873"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16323"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2020.20007"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6826"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.11.005"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.09.021"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15177"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003182\u2010y"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/15593258221105370"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S396430"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13348"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2024.103300"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.13209"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13586"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14435"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15596"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19400"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15524"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1735615"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.5070\/d3263047978"},{"key":"e_1_2_9_42_1","unstructured":"A Phase 3 Randomized Double\u2010Blind 52\u2010Week Placebo\u2010Controlled Multi\u2010Center Study Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult and Adolescent Participants With Non Segmental Vitiligo. ClinicalTrials.gov identifier: NCT05583526. Updated July 10 2025. Accessed October 13 2025 https:\/\/www.clinicaltrials.gov\/study\/NCT05583526."}],"container-title":["Skin Research and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/srt.70276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:18:17Z","timestamp":1761387497000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/srt.70276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/srt.70276"],"URL":"https:\/\/doi.org\/10.1111\/srt.70276","archive":["Portico"],"relation":{},"ISSN":["0909-752X","1600-0846"],"issn-type":[{"value":"0909-752X","type":"print"},{"value":"1600-0846","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70276"}}